Physician profile
William A Grass
NPI 1407854383
$5,869.02
in general payments reported to CMS, 2019-2025
63 companies · $645 in 2025
The $645 reported for 2025 was more than what 88% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,329 · 2022: $1,048 · 2023: $1,333 · 2024: $1,514 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $352.84 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $319.76 | 2021-2025 | Tecvayli, Rybrevant, Imbruvica |
| Daiichi Sankyo INC. | $271.43 | 2021-2025 | Enhertu |
| Pfizer INC. | $268.58 | 2021-2025 | |
| Gilead Sciences, INC. | $249.62 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $239.80 | 2022-2025 | |
| Celgene Corporation | $235.72 | 2021-2025 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $220.75 | 2021-2025 | Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $183.82 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $159.22 | 2021-2025 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $154.93 | 2022-2023 | Avastin, Rozlytrek, Tecentriq |
| Beigene USA, INC. | $148.36 | 2021-2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $137.49 | 2021-2024 | |
| Eisai INC. | $136.15 | 2021-2025 | |
| Genzyme Corporation | $132.12 | 2021-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $129.90 | 2021-2024 | Mektovi, Lorbrena, Braftovi |
| Rigel Pharmaceuticals, INC. | $128.76 | 2023-2024 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $123.44 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Pharmaessentia USA Corporation | $113.21 | 2024-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $113.00 | 2021-2024 | Zepzelca |
| Amgen INC. | $110.95 | 2021-2022 | |
| Glaxosmithkline, LLC. | $109.42 | 2023 | Jemperli, Zejula, Shingrix |
| Seagen INC. | $105.48 | 2021-2023 | Tukysa |
| Abbvie INC. | $103.08 | 2024-2025 | |
| Astellas Pharma US INC | $93.66 | 2021-2024 | Padcev, Xospata, Xtandi |
| Kite Pharma, INC. | $91.57 | 2022-2024 | Yescarta |
| Kyowa Kirin, INC. | $89.76 | 2021-2025 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $87.41 | 2021-2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $85.26 | 2021-2023 | Libtayo |
| Epizyme, INC. | $73.72 | 2021 | |
| Servier Pharmaceuticals LLC | $66.88 | 2022-2023 | |
| Tersera Therapeutics LLC | $65.97 | 2021-2023 | Zoladex |
| G1 Therapeutics, INC. | $62.19 | 2022-2023 | Cosela |
| Pharmacyclics LLC, An Abbvie Company | $60.44 | 2021-2022 | |
| Springworks Therapeutics, INC. | $59.37 | 2024-2025 | Ogsiveo |
| Myovant Sciences INC. | $55.54 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $49.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $47.02 | 2021-2024 | Onivyde |
| Stemline Therapeutics INC. | $45.77 | 2023-2024 | Orserdu |
| Cti Biopharma Corp. | $43.42 | 2023 | Vonjo |
| Adc Therapeutics America, INC. | $43.36 | 2022-2024 | |
| Puma Biotechnology, INC. | $43.00 | 2021-2024 | |
| Blueprint Medicines Corporation | $41.21 | 2021-2022 | |
| Emd Serono, INC. | $37.38 | 2023-2025 | Tepmetko |
| Sumitomo Pharma America, INC. | $29.90 | 2023-2025 | Orgovyx |
| Recordati_rare_diseases_inc. | $29.16 | 2025 | Enjaymo |
| Foundation Medicine, INC. | $28.67 | 2021 | |
| Iovance Biotherapeutics, INC. | $28.16 | 2025 | Amtagvi |
| Myriad Genetic Laboratories, INC. | $25.25 | 2021-2023 | Myrisk |
| Biocon Biologics INC | $24.80 | 2024 | Ogivri |
| Sobi, INC | $21.97 | 2025 | |
| Amneal Pharmaceuticals LLC | $20.87 | 2025 | Alymsys |
| Alexion Pharmaceuticals, INC. | $18.80 | 2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $17.92 | 2024 | Xpovio |
| Agios Pharmaceuticals, INC. | $17.38 | 2023 | Pyrukynd |
| Genmab U.S., INC. | $16.98 | 2023 | Epkinly |
| Dendreon Pharmaceuticals LLC | $16.53 | 2021 | |
| Morphosys, US INC. | $16.01 | 2023 | Monjuvi |
| Alnylam Pharmaceuticals INC. | $15.43 | 2023 | Onpattro |
| Clovis Oncology, INC. | $15.03 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.42 | 2024 | Cosela |
| Acrotech Biopharma INC. | $12.99 | 2022 | |
| Heron Therapeutics, INC. | $8.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Grass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.